Rituximab Extended Schedule or Retreatment Trial (RESORT) for Low Tumor Burden non-Follicular Indolent B-cell Non-Hodgkin Lymphomas: Eastern Cooperative Oncology Group Protocol E4402

E4402 (RESORT) was a phase 3 randomized prospective trial comparing maintenance rituximab (MR) versus a retreatment (RR) dosing strategy in asymptomatic, low tumor burden (GELF criteria) indolent lymphoma. A planned exploratory sub-study compared the two strategies for small lymphocytic (SLL) and ma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Williams, Michael E., Hong, Fangxin, Gascoyne, Randy D., Wagner, Lynne I., Krauss, John C., Habermann, Thomas M., Swinnen, Lode J., Schuster, Stephen J., Peterson, Christopher G., Sborov, Mark D., Martin, S. Eric, Weiss, Matthias, Ehmann, W. Christopher, Horning, Sandra J., Kahl, Brad S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4900920/
https://ncbi.nlm.nih.gov/pubmed/26970533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados